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Abstract
Background: Rapid and accurate diagnosis of tuberculosis (TB) is key to manage the disease and to control and
prevent its transmission. Many established diagnostic methods suffer from low sensitivity or delay of timely results
and are inadequate for rapid detection of Mycobacterium tuberculosis (MTB) in pulmonary and extra-pulmonary
clinical samples. This study examined whether a real-time polymerase chain reaction (RT-PCR) assay, with a turn-a-
round time of 2 h, would prove effective for routine detection of MTB by clinical microbiology laboratories.
Methods: A systematic literature search was performed for publications in any language on the detection of MTB
in pathological samples by RT-PCR assay. The following sources were used MEDLINE via PubMed, EMBASE, BIOSIS
Citation Index, Web of Science, SCOPUS, ISI Web of Knowledge and Cochrane Infectious Diseases Group Specialised
Register, grey literature, World Health Organization and Centres for Disease Control and Prevention websites. Forty-
six studies met set inclusion criteria. Generated pooled summary estimates (95% CIs) were calculated for overall
accuracy and bivariate meta-regression model was used for meta-analysis.
Results: Summary estimates for pulmonary TB (31 studies) were as follows: sensitivity 0.82 (95% CI 0.81–0.83),
specificity 0.99 (95% CI 0.99–0.99), positive likelihood ratio 43.00 (28.23–64.81), negative likelihood ratio 0.16 (0.12–0.
20), diagnostic odds ratio 324.26 (95% CI 189.08–556.09) and area under curve 0.99. Summary estimates for extra-
pulmonary TB (25 studies) were as follows: sensitivity 0.70 (95% CI 0.67–0.72), specificity 0.99 (95% CI 0.99–0.99),
positive likelihood ratio 29.82 (17.86–49.78), negative likelihood ratio 0.33 (0.26–0.42), diagnostic odds ratio 125.20
(95% CI 65.75–238.36) and area under curve 0.96.
Conclusions: RT-PCR assay demonstrated a high degree of sensitivity for pulmonary TB and good sensitivity for
extra-pulmonary TB. It indicated a high degree of specificity for ruling in TB infection from sampling regimes. This
was acceptable, but may better as a rule out add-on diagnostic test. RT-PCR assays demonstrate both a high
degree of sensitivity in pulmonary samples and rapidity of detection of TB which is an important factor in achieving
effective global control and for patient management in terms of initiating early and appropriate anti-tubercular
therapy.
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Background
Tuberculosis (TB), an infectious disease caused by the
bacillus Mycobacterium tuberculosis (MTB), is spread
from person to person predominantly through an air-
borne route. It remains a major global health problem as
it causes ill-health among millions of people. After the
human immunodeficiency virus (HIV), TB ranks as the
second leading cause of death from an infectious disease
worldwide [1, 2]. The lack of a simple and effective diag-
nostic test that can be utilised in resource-limited set-
tings, where the infection is endemic, has hindered its
control [3]. According to the World Health Organization
in 2015, there were 10.4 million new cases of TB world-
wide that resulted in 1.8 million deaths and over 95%
were from low- and middle-income countries [4, 5]. In
the UK, a total of 5758 TB cases were notified the by
Public Health England in 2015 [6].
Over the past decade, the TB diagnostics pipeline has
expanded, with several technologies showing promise
[7]. New diagnostic tests are continually being devel-
oped, driven by demands for improvements in speed,
cost, ease of use, patient safety and diagnostic accuracy
[8]. Consequently, there are often several tests available
for the diagnosis of a condition. Polymerase chain reac-
tion (PCR) technology was introduced in the mid-1990s
and has revolutionised the diagnosis of infectious dis-
eases. Nucleic acid amplification assays (NAAAs) are
commonly used in routine laboratories in industrialised
countries for rapid and specific detection of MTB com-
plex in clinical specimens. Over time, a significant im-
provement of PCR technologies has been achieved with
the development of real-time polymerase chain reaction
(RT-PCR) assay testing platforms. RT-PCR assay is com-
monly used to determine whether DNA or a sequence of
the MTB is present in a sample and detects amplified
DNA as the reaction progresses in real time. It monitors
the amplification of a targeted DNA/RNA molecule dur-
ing the PCR amplification by using complementary
primers, i.e. in real-time, and not at its end, as in con-
ventional PCR. A RT-PCR assay uses marked probes
with fluorophores that emit fluorescence alongside amp-
lification. The cycle of the PCR protocol in which there
appears significant fluorescence is proportional to the
quantity of DNA/RNA present in the sample. This value
is called cycle threshold (Ct) or cycle quantification (Cq).
RT-PCR is sensitive, specific and reproducible, and auto-
mation of the procedure reduces hands-on time and de-
creases the risk of cross-contamination [9].
RT-PCR-based methods have been shown to detect
MTB with higher sensitivity and specificity directly from
positive cultures or clinical specimens within 2 h [10]. It
requires approximately 6 copies/ml of MTB DNA in
comparison to smear microscopy that requires 5000–
10,000 bacilli/ml. For concentrated samples, such as
sputum, sensitivity of smear microscopy has been re-
ported to increase up to 39%. Culture which is the refer-
ence standard, requires at least 100 viable bacilli to
obtain a positive culture with a turn-a-round time of be-
tween 2 and 10 weeks [11]. Therefore, to adequately
treat and effectively control MTB, there is a need for ef-
fective, rapid and accurate diagnosis.
This review assesses all the available published primary
research studies to provide summary estimates of the ef-
fectiveness of RT-PCR assay for the detection of MTB
from pulmonary and extra-pulmonary samples. It sum-
marises current evidence-based clinical practice that can
help to develop future guidelines and healthcare policy
when choosing the most appropriate tool for rapid and
accurate detection of MTB in pathological samples on
routine basis.
Methods
This review is in accord with the standardised written
protocol (systematic review registration: PROSPERO
CRD42015027534) that followed the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses) statement guidelines [12]. Additional file 1
shows the PRISMA checklist. Quality of included studies
was assessed by Quality Assessment of Diagnostic Ac-
curacy Studies-2 (QUADAS-2) [13]. Institutional ethical
review approval was not needed for this review.
Strategy
Electronic searches
Search terms (included ‘tuberculosis’, ‘Mycobacterium tuber-
culosis’, ‘pulmonary tuberculosis’, ‘extra-pulmonary tubercu-
losis’, ‘real-time polymerase chain reaction’, ‘RT-PCR’, ‘nucleic
acid amplification test’, ‘culture-based media’, ‘liquid media’
and ‘solid media’) (see Additional file 2 for search terms)
were used to generate a list of primary studies in any lan-
guage from January 1995 to November 2016 (RT-PCR be-
came a tool for detecting and quantifying expression
profiles of selected genes in the mid-1990s. A search using
the key words real-time and PCR yielded seven publications
in 1995). Two investigators (EB, BC) independently and
systematically carried out the search. Searches using elec-
tronic bibliographic databases (MEDLINE via PubMed,
EMBASE, BIOSIS Citation Index, Web of Science, SCO-
PUS, ISI Web of Knowledge, Cochrane Infectious Diseases
Group Specialised Register (CIDG SR), Cochrane Registry
of Diagnostic Studies, National Institute for Health Re-
search, PROSPERO, Google Scholar Turning Research into
Practice (TRIP) and International Union Against Tubercu-
losis and Lung Disease (IUALTD)) took place in July 2015
and was updated in November 2016. The MEDLINE search
strategy is outlined in Additional file 2. The MEDLINE
search was imported to EMBASE, Cochrane Infectious Dis-
eases Group Specialised Register and other databases to
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identify additional records [14, 15]. These attempts to
avoid missing studies achieve a more reliable estimate of
diagnostic accuracy which is important to ensure that the
process of identifying studies is as thorough and unbiased
as possible.
We reviewed reference lists of included articles and any
relevant review articles identified through the above
methods. Conference Proceedings Citation Index-Science
(CPCI-S) was searched. We searched the portal of the
World Health Organization (WHO) International Clinical
Trials Registry Platform (http://www.who.int/trialsearch),
to identify ongoing trials and StopTB Partnership’s
New Diagnostics Working Group (www.stoptb.org/
wg/new_diagnostics/). Personal communication was sent
to the corresponding author of ‘Detection of Mycobacterial
DNA directly from FNAC samples of tuberculous
lymphadenopathy using real-time PCR: a preliminary
study’ to ask for study data. Forward citation searching of
relevant articles using the PubMed related articles and
relevant guidelines (i.e. National Institute for Health and
Care Excellence (NICE) in the UK) was performed. Focus
was placed on TB meetings for example annual scientific
conferences of TB diagnosis and control such as the
IUALTD. Besides full articles, abstracts and letters to the
editor with sample sizes >20 were also considered for
inclusion. There was no language limitation to the search.
Abstracts or articles in languages other than English were
screened using ‘Google Translator’.
Inclusion and exclusion criteria
Study designs such as cross-sectional studies, cohort
studies (prospective and retrospective) and case-control
designs for the detection of MTB from human patho-
logical samples of any patient age were eligible for inclu-
sion if the studies (1) described original research, (2)
compared RT-PCR assay to a reference/gold standard
method— culture-based (either liquid or solid) assay, (3)
reported total number of patients tested and positive/
negative results that allowed calculation of true positives
(TP), true negatives (TN), false positives (FP) and false
negatives (FN) and (4) were published between 1995 and
2016 in any language. Studies were excluded if (1) all
samples were not tested by reference/gold standard
test—culture-based (either liquid or solid) assay, (2) ap-
plication of RT-PCR assay for determining drug resist-
ance, (3) RT-PCR assay was not used in the study, (4)
reference test was a combination of greater than one
diagnostic test, (5) it included animal studies, (6) RT-
PCR assay was used for detecting non-tuberculosis
mycobacteria, (7) RT-PCR assay was used for detecting
MTB from clinical isolates and not the pathological
specimens/samples and (8) possible duplicate publica-
tion, when an author published more than one study.
The existence of overlapping study populations was
ascertained by checking sample recruitment sites and/or
periods. The article reporting on the largest number of
samples was included in our study.
Selection of studies
Full-text articles were screened independently (by EB
and BC, using a PRISMA flow chart [12]) for eligibility
for use in the study to minimise bias in selection. Any
disagreements were resolved through discussion and
where needed, by a third reviewer. Any rejected studies
were documented.
Data extraction
Data were extracted (independently by EB and BC) from
each selected study using a predetermined list of
categories/characteristics: participants/population, index
test, reference test, country, disease and target sequence
for detection of MTB DNA (Table 1).
Assessment of study quality
The methodological quality for the included studies was
assessed independently (EB and BC) according to the
four domains (patient selection, index test, reference
standard and flow and timing) of the QUADAS-2 tool
[13]. The study QUADAS-2 quality criteria are given in
Additional file 3.
Data synthesis and meta-analysis
For each study, we computed measures of test accuracy
using standard methods recommended for meta-analysis
of diagnostic studies: sensitivity, specificity, positive like-
lihood ratio (PLR), negative likelihood ratio (NLR), diag-
nostic odds ratio (DOR) and 95% confidence intervals
(CI) [16–18] see Additional file 4. TP, FP, TN and FN
were extracted directly from source papers. Where this
information was not available, values were calculated
from the data provided in the article. To assess the over-
all accuracy, a DOR was calculated using the
DerSimonian-Laird random-effect model, which ac-
counts for both within-study variability (random error)
and between-study variability (heterogeneity) along with
the area under the summary receiver operating charac-
teristic (SROC) curve using the bivariate model [17, 18].
The bivariate model considers potential threshold effects
and the correlation between binary tests (sensitivity and
specificity). These measures were pooled using the
random-effects model [17, 18]. Each study in the meta-
analysis contributed a pair of numbers: sensitivity and
specificity. Since these measures are correlated, we sum-
marised their joint distribution using a SROC curve. The
SROC curve presents a global summary of test perform-
ance and shows the trade-off between sensitivity and
specificity. A symmetric curve suggests that the variabil-
ity in accuracy between studies is explained, in part, by
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Table 1 Characteristics of the included studies
Author year [n] Country Total number of
samples (N)
Reference test: culture Index test RT-PCR Target sequence
PTB EPTB
Albuquerque, 2014 [24] Brazil 140 – LJ 7H9 TaqMan IS6110 gene
Antonenka, 2013 [25] Germany 116 – MGIT LJ TaqMan rpoB as target sequence
Armand, 2011 [26] France 70 47 LJ BacT/Alert MP TaqMan IS6110 gene
Barletta, 2014 [27] Belgium 112 – LJ Light Cycler 480
Real-time PCR assay
IS6110 gene
Bloemberg, 2013 [28] Switzerland 829 280 7H11 MGIT COBAS TaqMan 16S rRNA gene
Causse, 2011 [23] Spain – 340 LJ 7H9 COBAS TaqMan MTB 16S rRNA gene
Chadran, 2010 [29] India 72 – LJ MGIT 960 COBAS TaqMan IS6110 gene
Chaidir, 2012 [30] Indonesia – 207 Ogawa egg
medium MB/BacTalert
IS6110-PCR BioRad IS6110 gene
Chang, 2015 [31] South Korea 2859 – MGIT 960 3% Ogawa AdvanSure TB/NTM
Real-time PCR assay
IS6110 gene
Chen, 2012 [32] China 178 – BACTEC™ MGIT™ 960 Real-time PCR assay used
the ABI Prism SDS 7000
IS6110 gene
Chitnis, 2010 [33] India – 204 LJ MGIT-BACTEC Geno-Sen’s MTB complex
Real-time PCR assay
16S rRNA gene
Cho, 2015 [34] South Korea 2384 626 2% Ogawa medium
MGIT 960
COBAS TaqMan MTB assay IS6110 gene
Choe, 2011 [35] South Korea – 129 3% Ogawa TaqMan Real-time MTB PCR,
targeting the senX3-regX3
intergenic region
Choi, 2013 [36] South Korea 360 65 MGIT 960 COBAS TaqMan MTB assay IS6110 gene
Dayal, 2010 [37] India – 47 BacT/Alert Real-time PCR targeting
16SrRNA
using Light Cycler RNA
amplification syber green
1 kit (Roche Applied
Biosciences, Germany)
16S rRNA gene
El Khechine, 2009 [38] France – 134 BACTEC 9000 MB LJ Not specified IS6110 gene
Feizabadi, 2012 [39] Iran 247 – LJ TaqMan Cytochrome P450 Cyp
141 gene
Friedrich, 2011 [40] South Africa – 25 MGIT 960 Xpert rpoB probe
Gous, 2012 [41] South Africa – 39 BACTEC 9000 MB LJ Light Cycler mycobacterium
detection assay (LCTB)
Hillemann, 2011 [42] Germany – 521 MGIT 960 LJ GenoType MTBC and
CM/AS assays (Hain Lifescience)
rpoB probe
Hofmann-Thiel, 2016 [43] Germany 608 107 MGIT LJ Abbott Real-time MTB Antigen b (PAB) and the
multicopy insertion
element IS6110 gene
Huh, 2015 [44] South Korea 6852 – MGIT 960 LJ COBAS TaqMan 16S rRNA gene
In, 2014 [45] South Korea 247 – BACTEC MGIT 960 LJ Ultrafast NBS LabChip G2–3
(NanoBioSys)
Jönsson, 2015 [46] Sweden 2388 1005 MGIT 960 LJ COBAS TaqMan 16S rRNA gene
Kheawon, 2012 [47] Thailand 430 – LJ medium Commercial PCR Kits Amplicor IS6110 gene and
MPB64 gene
Kim, 2011 [48] South Korea 96 310 Solid culture Ultrafast NBS LabChip G2–3
system (NanoBioSys)
61 genomic DNA (gDNA)
samples of MTB
Lee, 2011 [49] South Korea 99 – 3% Ogawa AdvanSure TB/NTM Real-time
PCR assay
IS6110 gene
Lee, 2010 [50] South Korea – 143 3% Ogawa Light Cycler 2.0 senX3-regX3 intergenic
region
Lee, 2013 [51] Taiwan 587 – BACTEC MGIT 960 LJ COBAS TaqMan MTB assay IS6110 gene
Lim, 2014 [52] South Korea 1167 COBAS TaqMan MTB assay
Linasmita, 2012 [53] Thailand – 73 MGIT 960 COBAS TaqMan MTB assay 16S ribosomal RNA
gene of M. tuberculosis
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differences in thresholds used by the studies. The area
under the SROC curve is a global measure of overall
performance of the test. An area under the curve value
of 1 indicates perfect discriminatory ability of the test,
while an area under the curve value of 0.5 means that
the test does not have discriminating ability [17, 18].
Data were analysed using Meta-DiSC (version 1.4),
Reviewing Manager ver. 5.3 (Cochrane Collaboration,
Oxford, UK) [18, 19]. The data were displayed
graphically on forest plots and SROC plots. The
SROC curve was fitted using the Littenberg-Moses
method [20].
Publication bias was not evaluated as this is not usu-
ally recommended in the meta-analysis for diagnostic
test accuracy [21]. Generally, a diagnostic accuracy study
does not test a hypothesis; therefore, there is no p value
for authors and publishers that may influence decisions
about publication which are based on the statistical sig-
nificance of the results [22].
Investigations of heterogeneity
Exploring heterogeneity is a critical issue (1) to under-
stand the possible factors that influence accuracy esti-
mates and (2) to evaluate the appropriateness of
statistical pooling of accuracy estimates using random-
effects meta-analysis to generate sensitivity and specifi-
city with 95% CIs from various studies [22].
The heterogeneities among studies were assessed visu-
ally with forest plots and SROC curves with 95% predic-
tion regions and statistically with chi-squared (χ2) and
using I-squared (I2) statistics with the following inter-
pretation: I2 = 0, no heterogeneity; 0 < I2 < 25, mild het-
erogeneity; 25 ≤ I2 < 50, moderate heterogeneity;
50 ≤ I2 < 75, strong heterogeneity; 75 ≤ I2 < 90, consid-
erable heterogeneity and 90 ≤ I2, extreme heterogeneity
[23]. Source of heterogeneity was investigated using
stratified (subgroup) analyses. The following factors were
specified a priori as potential sources of heterogeneity
(1) studies of RT-PCR assay type: CobasTaqMan as the
RT-PCR assay, Light Cycler as the RT-PCR assay, Ce-
pheid & others and (2) RT-PCR assay target sequence
gene: IS6110 as the RT-PCR assay target sequence gene,
16SRNA as the RT-PCR assay target sequence gene and
other genes as the RT-PCR assay (see Tables 1, 3 and 4).
Results
Study characteristics
Of the 6706 references that were identified initially, 1628
potentially relevant citations were selected based on
relevance to the study topic. An additional 27 studies
Table 1 Characteristics of the included studies (Continued)
Author year [n] Country Total number of
samples (N)
Reference test: culture Index test RT-PCR Target sequence
PTB EPTB
Lira, 2013 [54] Brazil 165 – LJ ABI Prism 7500 Sequence
Detection System (Applied
Biosystems) using
TaqMan-specific probe
IS6110 gene
Luo, 2010 [55] USA – 70 Culture-based assay
(type not stated)
SmartCycler II instrument IS6110 gene
Malhotra, 2012 [56] India – 555 7H9 COBAS Taqman IS6110 gene
Mangat, 2016 [57] India 74 – MGIT 960 LJ Roche Light Cycler 480
Real-time PCR system
123 bp fragment of
insertion element IS6110
sequence
Miller, 2011 [58] North Carolina, USA 89 23 7H9 LJ Xpert Laboratory-developed
test targeting IS6110 gene
Moure, 2012 [59] Spain – 149 MGIT 960 LJ GX assay
Park, 2013 [60] South Korea 320 – MGIT 960 3% Ogawa COBAS TaqMan IS6110 gene
Pinhata, 2015 [61] Brazil 715 – MGIT 960 Ogawa–Kudoh slant Roche Light Cycler 480 II system mpt64 gene
Rachow, 2011 [11] Tanzania 292 – Both liquid and solid (type not stated) Cepheid Xpert MTB/RIF assay rpoB as target gene
Rosso, 2011 [62] Brazil – 158 LJ ABI Prism 7500 system
(Applied Biosystems)
IS6110 gene
Sethi, 2012 [63] India 50 22 MGIT 960 LJ In-house mpt64 Real-time PCR mpt64 gene
Sharma, 2015 [64] India 1480 – MGIT 960 LJ ABI prism 3130xl genetic
analyser (Applied Biosystems)
81-bp rpoB gene
Tortoli, 2012 [65] Italy 4340 1727 MGIT 960 LJ Cepheid Xpert MTB/RIF assay rpoB as target gene
Wang, 2013 [66] China 30 – Bact/Alert 3D Light Cycler 480 (Roche)
Yang, 2011 [67] Taiwan 1093 – MGIT 960 LJ 7H11 COBAS TaqMan MTB assay IS6110 gene
Key: LJ Löwenstein-Jensen, Middlebrook 7H9 Broth Liquid growth medium, Middlebrook 7H11 Solid medium, MGIT Mycobacterium Growth Indicator Tube, PTB
Pulmonary TB, EPTB Extra-pulmonary TB, [n] reference list number
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were identified from grey literature and references of
full-text articles. After screening all the titles and ab-
stracts, removing the duplicates and excluding the ineli-
gible studies, 46 articles [10, 23–67] were selected for
full-text review and meta-analysis (Fig. 1). Twenty-one
[10, 24, 25, 27, 29, 31, 32, 39, 44, 45, 47, 49, 51, 52, 54,
57, 60, 61, 64, 66, 67] reported detection of pulmonary
TB (PTB), fifteen [23, 30, 33, 35, 37, 38, 40–42, 50, 53,
55, 56, 59, 62] reported detection of extra-pulmonary
TB (EPTB) and ten [26, 28, 34, 36, 43, 46, 48, 58, 63, 65]
reported on both types of pathological sample. Table 1
summarises the main characteristics of the included
studies. In total, the review and meta-analysis included
35,380 (28,406 PTB and 6974 EPTB) pathological sam-
ples obtained from 21 countries with high, moderate
and low prevalence of TB. Studies included patients with
infections identified in primary, secondary and tertiary
healthcare settings. Details of the RT-PCR assays used
are summarised in Table 1.
The methodological quality of studies (assessed by the
QUADAS-2 tool) was generally high, with 37 of the
studies meeting all four domains of the criteria (see
Figs. 2 and 3). All studies used RT-PCR assay as index
test and culture-based assay as the reference test.
Meta-analysis
Results as 95% CI values were as follows: overall sensi-
tivity 0.82 (95% CI 0.81–0.83) and 0.70 (95% CI 0.67–
0.72) and the values and confidence intervals for specifi-
city are similar 0.99 (95% CI 0.99–0.99) for PTB and
EPTB samples, respectively. AUC was 0.99 and 0.96 for
PTB and EPTB samples, respectively. The summary esti-
mates of PTB for heterogeneity with chi-squared (χ2)
using 95% CI for sensitivity, specificity, PLR, NLR and
DOR were 586.21, 361.23, 285.01, 359.13 and 242.84, re-
spectively, and p = 0 indicating significant heterogeneity
across studies. I2 was between 87.60 and 92.80% showing
significant heterogeneity. The summary estimates of
EPTB heterogeneity with chi-squared (χ2) using 95% CI
for sensitivity, specificity, PLR, NLR and DOR were
272.48, 105.48, 75.37, 186.30 and 70.73, respectively, and
p = 0 indicating significant heterogeneity across studies.
I2 was between 66.10 and 91.20% showing significant
heterogeneity. There were considerable heterogeneities
(see Table 2, Figs. 4 and 5) in these data.
Subgroup analyses by RT-PCR assay type
I. With CobasTaqMan (Table 1) as the RT-PCR assay
(17 studies, 19,814 specimens), the results were as
follows: sensitivity 0.78 (95% CI 0.76–0.80), specifi-
city 10.99 (95% CI, 0.99–0.99) and AUC 0.98. A test
with perfect discrimination has a ROC curve that
passes through the upper left corner (100%
sensitivity, 100% specificity). The closer the ROC
curve to the upper left corner, the higher the overall
accuracy of the test. The summary estimates of
CobasTaqMan heterogeneity with chi-squared (χ2)
using 95% CI for sensitivity, specificity, PLR, NLR
and DOR were 205.13, 127.21, 98.14, 134.36 and
47.6, respectively, and p = < 0.001 indicating signifi-
cant heterogeneity across studies. I2 was between
70.50 and 91.20% showing significant heterogeneity.
The results for subgroup analysis by RT-PCR assay
type are as presented in Table 3 and Additional file 5
and show considerable heterogeneity.
II. With Light Cycler (Table 1) as the RT-PCR assay (7
studies, 1159 specimens), the results were as follows:
sensitivity 0.85 (95% CI 0.80–0.88), specificity 0.99
(95% CI 0.98–0.99) and AUC 0.97. A test with per-
fect discrimination has a ROC curve that passes
through the upper left corner (100% sensitivity,
100% specificity). The closer the ROC curve to the
upper left corner, the higher the overall accuracy of
the test. The summary estimates of Light Cycler het-
erogeneity with chi-squared (χ2) using 95% CI for
sensitivity, specificity, PLR, NLR and DOR were
61.71, 10.09, 17.45, 63.77, 20.35 respectively and
p = < 0.121 indicating significant heterogeneity
across studies. I2 was between 66.40 and 90.30%
showing significant heterogeneity. The results for
subgroup analysis by RT-PCR assay type are as pre-
sented Table 3 and Additional file 5 and show con-
siderable heterogeneity.
III.With Cepheid and others (Table 1) as the RT-PCR
assay (22 studies, 14,839 specimens), the results were
as follows: sensitivity 0.78 (95% CI 0.77–0.80), speci-
ficity 0.99 (95% CI 0.99–0.99) and AUC 0.99. A test
with perfect discrimination has a ROC curve that
passes through the upper left corner (100% sensitiv-
ity, 100% specificity). The closer the ROC curve to
the upper left corner, the higher the overall accuracy
of the test. The summary estimates of Cepheid and
others heterogeneity with chi-squared (χ2) using 95%
CI for sensitivity, specificity, PLR, NLR and DOR
were 729.43, 299.13, 234.62, 594.30 and 208.25, re-
spectively, and p = 0 indicating significant hetero-
geneity across studies. I2 was between 89.90 and
97.10% showing significant heterogeneity. The results
for subgroup analysis by RT-PCR assay type are as
presented Table 3 and Additional file 5 and show
considerable heterogeneity.
Subgroup analyses by RT-PCR assay target sequence
gene
I. With IS6110 as the RT-PCR assay target sequence
gene (22 studies, 12,004 specimens), the results were
Babafemi et al. Systematic Reviews  (2017) 6:215 Page 6 of 16
PRISMA 2009 Flow Diagram
Id
en
ti
fi
ca
ti
o
n
S
cr
ee
n
in
g
E
lig
ib
ili
ty
In
cl
u
d
ed
Records identified through 
database searching 
(n = 1628)
Additional records identified 
through other sources 
(n = 27)
Records after duplicates removed 
(n =1488)
Records screened 
(n = 1488)
Full-text articles 
assessed for eligibility 
(n =141)
Studies included in 
qualitative synthesis 
(n =46)
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =46)
Records excluded 
(n = 1347)
Full-text articles excluded, with 
reasons 
(n =95)
Reasons for exclusion:
Culture-based not included 
as reference or 
combined with another 
assay when included: 
65
Insufficient data (e.g. not 
reporting 2X2, abstract 
only): 14
Studies involving clinical 
isolates: 6
Animal/zoonotic studies: 3
Conventional PCR not RT-
PCR assay studies: 7
Fig. 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Fig. 2 Risk of bias and applicability concerns graph: review authors’ judgements about each domain presented as percentages across
included studies
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as follows: sensitivity 0.79 (0.77–0.81), specificity
0.98 (0.98–0.98) and AUC 0.99. A test with per-
fect discrimination has a ROC curve that passes
through the upper left corner (100% sensitivity,
100% specificity). The closer the ROC curve to
the upper left corner, the higher the overall ac-
curacy of the test. The summary estimates of
IS6110 heterogeneity with chi-squared (χ2) using
95% CI for sensitivity, specificity, PLR, NLR and
DOR were 470.30, 150.16, 134.64, 356.22 and
141.04, respectively, and p = 0 indicating signifi-
cant heterogeneity across studies. I2 was between
85.10 and 95.50% showing significant heterogen-
eity. The results for subgroup analysis by RT-PCR
assay target sequence gene are presented in
Table 4 and Additional file 5 and show consider-
able heterogeneity.
II. With 16S rRNA as the RT-PCR assay target se-
quence gene (7 studies, 12,074 specimens), the re-
sults were as follows: sensitivity 0.69 (0.66–0.71),
specificity 0.99 (0.99–0.99) and AUC 0.97. A test
with perfect discrimination has a ROC curve that
passes through the upper left corner (100% sensitiv-
ity, 100% specificity). The closer the ROC curve to
the upper left corner, the higher the overall accuracy
of the test (χ2) using 95% CI for sensitivity, specifi-
city, PLR, NLR and DOR were 45.85, 32.10, 34.60,
19.87 and 9.12, respectively, and p < 0.167 indicating
significant heterogeneity across studies. I2 was
between 86.90 and 34.20% showing significant
Fig. 3 Risk of bias and applicability concerns summary: review authors’ judgements about each domain for each included study
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Table 2 Summary of statistical results for pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) pathological
samples
Test property Summary measure of
test accuracya (95%
CI)
Test for heterogeneity
(χ2) (df = 24) (I2) p value
PTB (n = 31; b28,406) AUC = 0.99
Sensitivity 0.82 (0.81–0.83) 586.21 92.8% < 0.001
Specificity 0.99 (0.99–0.99) 361.23 91.7% < 0.001
Positive likelihood ratio (PLR) 42.77 (28.23–64.81) 285.01 89.5% < 0.001
Negative likelihood ratio (NLR) 0.16 (0.12–0.20) 359.13 91.6% < 0.001
Diagnostic odds ratio (DOR) 324.26 (189.08–556.09) 242.84 87.6% < 0.001
EPTB (n = 25; b6974) AUC = 0.96
Sensitivity 0.70 (0.67–0.72) 272.48 91.20% < 0.001
Specificity 0.99 (0.99–0.99) 105.48 77.20% < 0.001
Positive likelihood ratio (PLR) 29.82 (17.86–49.78) 75.37 68.20% < 0.001
Negative likelihood ratio (NLR) 0.33 (0.26–0.42) 186.30 87.10% < 0.001
Diagnostic odds ratio (DOR) 125.20 (65.76–238.36) 70.73 66.10% < 0.001
χ2 chi-squared, df degree of freedom, I2 I-squared, n number of studies, CI confidence interval, AUC area under receiver operating characteristics curve, PTB pul-
monary tuberculosis, EPTB extra-pulmonary tuberculosis
aRandom-effects model
bNumber of specimens
Fig. 4 Forest plot of estimates of RT-PCR assay for pulmonary tuberculosis (PTB). TP = true positive, FP = false positive, FN = false negative, TN =
true negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study
(blue squares) and its 95% CI (black horizontal line)
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Fig. 5 Forest plot of estimates of RT-PCR assay for extra-pulmonary tuberculosis (EPTB). TP = true positive, FP = false positive, FN = false negative,
TN = true negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the
study (blue squares) and its 95% CI (black horizontal line)
Table 3 Subgroup analyses by RT-PCR assay type
RT-PCR assay type Summary measure of
test accuracya (95%
CI)
Test for heterogeneity
(χ2) (df = 24) (I2) p value
CobasTaqMan (n = 17; b19,814) AUC = 0.98
Sensitivity 0.78 (0.76–0.80) 205.13 92.20% < 0.001
Specificity 0.99 (0.99–0.99) 127.21 87.40% < 0.001
Positive likelihood ratio (PLR) 41.59 (27.80–62.18) 98.14 83.70% < 0.001
Negative likelihood ratio (NLR) 0.18 (0.13–0.23) 134.36 88.10% < 0.001
Diagnostic odds ratio (DOR) 273.14 (181.45–411.17) 47.6 66.40% < 0.001
Light Cycler (n = 7; b1159) AUC = 0.97
Sensitivity 0.85 (0.80–0.88) 61.71 90.30% < 0.001
Specificity 0.99 (0.98–0.99) 10.09 40.50% 0.121
Positive likelihood ratio (PLR) 21.65 (6.82–68.72) 17.45 65.60% 0.008
Negative likelihood ratio (NLR) 0.17 (0.08–0.38) 63.77 90.60% < 0.001
Diagnostic odds ratio (DOR) 150.52 (31.97–708.78) 20.35 70.50% < 0.002
Cepheid and others (n = 22; b14,839) AUC = 0.99
Sensitivity 0.78 (0.77–0.80) 729.43 97.10% < 0.001
Specificity 0.99 (0.99–0.99) 299.13 93.00% < 0.001
Positive likelihood ratio (PLR) 38.50 (19.65–75.42) 234.62 91.00% < 0.001
Negative likelihood ratio (NLR) 0.22 (0.15–0.33) 594.30 96.50% < 0.001
Diagnostic odds ratio (DOR) 221.44 (94.94–516.51) 208.25 89.90% < 0.001
χ2 chi-squared, df degree of freedom, I2 I-squared, n number of studies, CI confidence interval, AUC area under receiver operating characteristics curve
aRandom-effects model
bNumber of specimens
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heterogeneity. The results for subgroup analysis by
RT-PCR assay target sequence gene are presented in
Table 4 and Additional file 5 and show considerable
heterogeneity.
III.With other genes (see Table 1) as the RT-PCR
assay (17 studies, 11,870 specimens) the results
were as follows: sensitivity 0.82 (0.80–0.84), speci-
ficity 0.99 (0.99–0.99) and AUC 0.98. A test with
perfect discrimination has a ROC curve that
passes through the upper left corner (100% sensi-
tivity, 100% specificity). The closer the ROC curve
to the upper left corner, the higher the overall ac-
curacy of the test. The summary estimates of
other genes heterogeneity with chi-squared (χ2)
using 95% CI for sensitivity, specificity, PLR, NLR
and DOR were 413.02, 173.35, 123.92, 498.03 and
125.08, respectively, and p < 0.001 indicating sig-
nificant heterogeneity across studies. I2 was be-
tween 87.20 and 96.10% showing significant
heterogeneity. The results for subgroup analysis by
RT-PCR assay target sequence gene are presented
in Table 4 and Additional file 5 and show consid-
erable heterogeneity.
Discussion
Tuberculosis is a global health threat and early and accur-
ate diagnosis is crucial for preventing morbidity and mor-
tality. Various methods are employed for the diagnosis of
TB such as smear microscopy, culture identification,
histopathology, tuberculin skin test (TST), serological as-
says, interferon-gamma release assays (IGRAs) and nu-
cleic acid amplification (NAA) tests [68, 69]. Smear
microscopy is widely used in the diagnosis of TB but has
drawbacks owing to low and variable sensitivity values (0–
40%) and cannot readily differentiate between MTB and
non-tuberculous mycobacteria (NTM) [70–72]. Culture
identification for MTB also has variable sensitivities (0–
80%) in different TB specimens [63, 73–75] with turn-a-
round time of 2–10 weeks requiring the use of skilful
technicians [76]. Diagnosis of TB from tissue samples is
usually made by histopathological examination that de-
pends on the presence of granulomatous inflammation
and caseous necrosis [70, 77]. However, histology does not
distinguish between EPTB and infections from other
granulomatous diseases such as NTM, sarcoidosis, leprosy
and systemic lupus erythematosus (except for the pres-
ence of acid-fast bacilli (AFB)) [78, 79]. RT-PCR is a novel
Table 4 Subgroup analyses by RT-PCR assay target sequence gene
RT-PCR assay genes Summary measure of
test accuracya (95%
CI)
Test for heterogeneity
(χ2) (df = 24) (I2) p value
IS6110 (n = 22; b12,004) AUC = 0.99
Sensitivity 0.79 (0.77–0.81) 470.30 95.50% < 0.001
Specificity 0.98 (0.98–0.98) 150.16 86.00% < 0.001
Positive likelihood ratio (PLR) 31.76 (20.12–50.13) 134.64 84.40% < 0.001
Negative likelihood ratio (NLR) 0.17 (0.12–0.24) 356.22 94.10% < 0.001
Diagnostic odds ratio (DOR) 243.69 (127.07–437.37) 141.04 85.10% < 0.001
16S rRNA (n = 7; b12,074) AUC = 0.97
Sensitivity 0.69 (0.66–0.72) 45.85 86.90% < 0.001
Specificity 0.99 (0.99–0.99) 32.10 81.30% < 0.001
Positive likelihood ratio (PLR) 67.64 (36.40–125.70) 34.60 82.50% < 0.001
Negative likelihood ratio (NLR) 0.29 (0.24–0.36) 19.87 69.8% 0.003
Diagnostic odds ratio (DOR) 287.19 (193.85–425.46) 9.12 34.20% 0.167
Other genes (n = 17; b11,870) AUC = 0.98
Sensitivity 0.82 (0.80–0.84) 413.02 96.10% < 0.001
Specificity 0.99 (0.99–0.99) 173.35 90.80% < 0.001
Positive likelihood ratio (PLR) 42.48 (20.66–87.36) 123.92 87.10% < 0.001
Negative likelihood ratio (NLR) 0.22 (0.13–0.37) 498.03 96.80% < 0.001
Diagnostic odds ratio (DOR) 234.56 (86.01–639.63) 125.08 87.20% < 0.001
χ2 chi-squared, df degree of freedom, I2 I-squared, n number of studies, CI confidence interval, AUC area under receiver operating characteristics curve, IS6110
Mycobacterium tuberculosis complex-specific insertion sequence, 16S rRNA 16S ribosomal RNA gene of MTB, Other genes rpoB as target sequence, mpt64 gene, 81-
bp rpoB gene, senX3-regX3 intergenic region, 61 genomic DNA (gDNA) samples of MTB, cytochrome P450 Cyp 141 gene
aRandom-effects model
bNumber of specimen
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and robust assay primarily used to quantify the nucleic
acids in all TB specimens [63, 80–82]. The main advan-
tages of RT-PCR are shortened turn-a-round time, quanti-
fication of bacterial load and automation of the procedure
that reduces hands-on time and decreased risk of cross-
contamination [63, 83]. This review provides evidence on
the effectiveness of RT-PCR assay for the rapid and accur-
ate detection of MTB from pathological samples. To our
knowledge, this is the first systematic review and meta-
analysis for ascertaining the effectiveness of RT-PCR as-
says for the detection of MTB from both pulmonary and
extra-pulmonary pathological samples.
In this study, results indicated that RT-PCR assay pro-
duces consistent results with high specificity of 0.99
(95% CI 0.99–0.99), PLR of 43.0 (28.23–64.81) and NLR
of 0.16 (0.12–0.20) for PTB, whereas specificity, PLR
and NLR were 0.99 (95% CI, 0.99–0.99), 29.82 (17.86–
49.78) and 0.33 (0.26–0.42), respectively, for EPTB. A
PLR of 43 suggests that patients with a pulmonary MTB
infection have a 43-fold higher chance of being RT-PCR
test positive compared with patients without the infec-
tion. This ratio suggests a potential role for RT-PCR
assay in confirming (ruling in) a MTB infection.
The summary estimates of sensitivity, however, were
0.82 (95% CI 0.81–0.83) and 0.70 (95% CI 0.67–0.72) for
pulmonary and extra-pulmonary samples, respectively,
higher in pulmonary than extra-pulmonary TB possibly
due to paucity of tubercle bacilli in extra-pulmonary
samples. Sensitivity estimates were more variable than
specificity. According to the AUC and the DOR (see
Table 2), diagnostic accuracy of RT-PCR assay was excel-
lent for the pulmonary specimens over extra-pulmonary
and these results are acceptable for clinical practice (see
Table 2).
A RT-PCR assay for the detection of MTB has a high
sensitivity and specificity. The PLR and NLR showed
that RT-PCR may serve as a suitable method when con-
firming or excluding TB. It was anticipated that there
would be some degree of heterogeneity of diagnostic
measures across studies due to differences in sample
size, RT-PCR assay type, reference test (either liquid or
solid or both) and TB prevalence. High heterogeneity
was found among studies (as defined by the χ2 and I2
statistics) for all measures. Subgroup analyses were
therefore performed pre-specified to investigate potential
sources of the observed between-study heterogeneity. It
was assumed that the disparity was likely a result of the
differences in the type of index test (RT-PCR assay) or
target sequence gene of MTB used.
In the current study, a limited number of subgroup
analyses were conducted by comparing CobasTaqMan,
Light Cycler, Cepheid and others as RT-PCR assay types
to reduce the degree of study heterogeneity. Heterogen-
eity assessed by χ2 and I2 statistics between these
subgroups was generally not very strong (see Table 3).
However, significant heterogeneity of diagnostic accur-
acy measures was expected and was, indeed, found
among studies and the random-effects model partially
accounted for the between-study heterogeneity.
Some degree of heterogeneity of diagnostic measures
across studies was found due to differences in sample
size, study design, target genes and clinical settings of
the participants. Thus, it is possible that when evaluating
RT-PCR assays using a more sensitive index test can
lead to overestimation of the assay’s sensitivity. No sig-
nificant differences in specificities of the different types
of index tests were observed.
Strengths and weaknesses of the review
An important strength of this study was its comprehen-
sive search strategy using several search engines to iden-
tify any unpublished studies in the form of conference
abstracts or proceedings. Screening, study selection,
quality assessment and data extraction were undertaken
independently and reproducibly by two reviewers, as
such human error should be limited. The problem of
missing data was reduced by contacting the authors of
the publications. In accordance with the study guide-
lines, potential publication bias and heterogeneity was
explored [15, 84]. Evaluation of level of publication bias
was not formally carried out in the study; however, the
risk of this bias was reduced by not restricting the search
to any language. In addition, we contacted experts for
information on additional studies. Another strength of
this review is that RT-PCR assay has comparably high
sensitivity with paucibacillary specimens and high
throughput capacities.
This review does, however, have some limitations in
assessing issues such as cost-effectiveness and the net ef-
fect of RT-PCR assay on clinical care and patient out-
comes. Also, because of poor reporting, an analysis of
the effect of factors such as laboratory infrastructure was
not possible. Secondly, empirical evidence suggests that
studies with significant or favourable results are more
likely to be published than those with non-significant or
unfavourable results [85]. In addition, literature search
strategies are inherently imperfect and studies can be
missed, it is therefore possible that a proportion of such
studies with non-significant or unfavourable results may
have been missed. Other limitations are conflicts of
interest of study authors particularly from industry sup-
ported studies and fully keeping up to date with the pri-
mary studies in this rapidly evolving field.
Given that RT-PCR assays in this review cover a wide
range of different target genes and procedures, it is not
possible to recommend any one over another owing to a
lack of direct test comparisons. Our findings should be
interpreted in the context of the quality of studies and
Babafemi et al. Systematic Reviews  (2017) 6:215 Page 12 of 16
reporting and variability in study quality. Diagnostic
studies in general [86] and TB diagnostic studies in par-
ticular [87] seem to be beset by these problems.
Implications for research and clinical practice
Current evidence suggests a potential role for RT-PCR
assay in confirming a diagnosis of TB. It offers an alter-
native robust approach to detect MTB in paucibacillary
EPTB samples that provides rapid results with good
diagnostic accuracy. The results of this assay type should
be interpreted in parallel with clinical findings and the
results of conventional tests; but the assay contributes
significantly for an early diagnosis and exerts an impact
on clinical management and control of TB. Our findings
do not support the use of this assay type for excluding
diagnosis of tuberculosis as standalone test.
For EPTB, clinical judgement has both poor sensitivity
and specificity. The NICE guidelines recommend the use
of culture, histology and/or chest X-ray for patients with
non-respiratory TB [88]. Consequently, outcomes of a
negative smear for acid-fast bacilli, lack of granulomas
on histopathology and failure to culture MTB do not ex-
clude the diagnosis of EPTB; RT-PCR assay has proved
to be a novel diagnostic modality in varied forms of
EPTB. This review suggests RT-PCR assay can be of help
as a most specific test in a ‘rule-in decision’ for MTB
detection.
The reliability of RT-PCR to confirm an early diagnosis
of TB meningitis and abdominal TB has been well estab-
lished when smear and culture tests are rarely positive
[89, 90]. It has also proved useful for an early diagnosis
of osteoarticular TB in tissue samples and that can help
to start timely, appropriate anti-tubercular therapy
(ATT) [91] and prevent progression to irreversible tissue
changes. Due to small sample volumes available, irregu-
lar dispersion of MTB in specimens both viable and
non-viable, RT-PCR has aided in detecting MTB com-
pared with conventional tests from an array of different
cases of EPTB such as pericardial tuberculosis, dissemi-
nated/miliary tuberculosis, thyroid tuberculosis, ocular
tuberculosis, tuberculous mastitis and others [90].
Future studies should compare commercialised RT-
PCR assays to determine their diagnostic accuracy. The
use of guidelines such as the Standards for Reporting of
Diagnostic Accuracy (STARD) might improve the quality
of reporting of primary studies [92]. Further work is re-
quired to devise a simple and cost-effective RT-PCR test
for an efficient diagnosis of TB that can be used rou-
tinely in resource-poor countries.
Conclusion
According to this review and meta-analysis, RT-PCR
assay has a high sensitivity and specificity for PTB with
turn-a-round time of 2 h compared with reference
culture-based assay that takes between 2 and 10 weeks
for detection. Overall, RT-PCR assay accuracy was su-
perior for pulmonary samples (sensitivity 0.82 (95% CI
0.81–0.83); specificity 0.99 (95% CI 0.99–0.99)) as op-
posed to extra-pulmonary samples (sensitivity 0.70 (95%
CI 0.67–0.72); specificity 0.99 (95% CI 0.99–0.99)) pos-
sibly due to paucibacillary. The specificity was high for
both pulmonary and extra-pulmonary samples indicating
that the test should be adopted as the first-line test for
ruling in TB infection but may need to be an add-on test
to rule out the disease. It offers an alternative robust ap-
proach to detect MTB in paucibacillary EPTB samples,
showing rapid results with good diagnostic accuracy.
The results of this assay should be interpreted in parallel
with clinical findings and the results of conventional
tests, but the assay may contribute significantly for an
early diagnosis and exert an impact on the clinical man-
agement and control of TB. The findings do not support
the use of this assay for excluding a diagnosis of TB on
its own as a standalone test. It offers an incremental
benefit as an add-on test to other investigations. RT-
PCR assays, combining amplification and detection in a
single run, seem to offer advantages over conventional
assays including the reference standard.
From the data of investigations of heterogeneity, fac-
tors such as RT-PCR assay types (CobasTaqMan, Light
Cycler, Cepheid and others) and RT-PCR assay target se-
quence genes (IS6110, 16SRNA and other genes) were
considered to have influenced the accuracy estimates.
It is anticipated that our findings will aid healthcare
practitioners and policymakers in adopting the use of
this assay on a routine basis. Most importantly, this can
be as a point-of-care-test which will help in the global
control of MTB, particularly in developing countries
with a high burden of the disease.
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